These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 25003355)

  • 41. Hypomethylating agents and other novel strategies in myelodysplastic syndromes.
    Garcia-Manero G; Fenaux P
    J Clin Oncol; 2011 Feb; 29(5):516-23. PubMed ID: 21220589
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
    Pusic I; Choi J; Fiala MA; Gao F; Holt M; Cashen AF; Vij R; Abboud CN; Stockerl-Goldstein KE; Jacoby MA; Uy GL; Westervelt P; DiPersio JF
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1761-9. PubMed ID: 26055299
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and efficacy of azacitidine in myelodysplastic syndromes.
    Vigil CE; Martin-Santos T; Garcia-Manero G
    Drug Des Devel Ther; 2010 Sep; 4():221-9. PubMed ID: 20957213
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
    Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
    Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug therapy for myelodysplastic syndrome: building evidence for action.
    Tefferi A; Letendre L
    Cancer; 2006 Apr; 106(8):1650-2. PubMed ID: 16532501
    [No Abstract]   [Full Text] [Related]  

  • 46. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine.
    Borthakur G; Ahdab SE; Ravandi F; Faderl S; Ferrajoli A; Newman B; Issa JP; Kantarjian H
    Leuk Lymphoma; 2008 Apr; 49(4):690-5. PubMed ID: 18398735
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7.
    Rüter B; Wijermans P; Claus R; Kunzmann R; Lübbert M
    Blood; 2007 Aug; 110(3):1080-2; author reply 1083. PubMed ID: 17644749
    [No Abstract]   [Full Text] [Related]  

  • 48. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?
    Steensma DP
    Best Pract Res Clin Haematol; 2012 Dec; 25(4):443-51. PubMed ID: 23200541
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.
    Cashen AF; Schiller GJ; O'Donnell MR; DiPersio JF
    J Clin Oncol; 2010 Feb; 28(4):556-61. PubMed ID: 20026803
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
    Kantarjian H; Oki Y; Garcia-Manero G; Huang X; O'Brien S; Cortes J; Faderl S; Bueso-Ramos C; Ravandi F; Estrov Z; Ferrajoli A; Wierda W; Shan J; Davis J; Giles F; Saba HI; Issa JP
    Blood; 2007 Jan; 109(1):52-7. PubMed ID: 16882708
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting DNA methylation.
    Issa JP; Kantarjian HM
    Clin Cancer Res; 2009 Jun; 15(12):3938-46. PubMed ID: 19509174
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oral hypomethylating agents: beyond convenience in MDS.
    Griffiths EA
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):439-447. PubMed ID: 34889435
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes.
    Wang R; Gross CP; Maggiore RJ; Halene S; Soulos PR; Raza A; Galili N; Ma X
    Leuk Res; 2011 Jul; 35(7):904-8. PubMed ID: 21067809
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
    Liu W; Zhou Z; Chen L; Wang X
    Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndromes.
    Carella AM
    Eur J Haematol; 2015 Jun; 94(6):463. PubMed ID: 25702976
    [No Abstract]   [Full Text] [Related]  

  • 56. [Decitabine treatment in myelodysplastic syndromes--results of a compassionate patient program in Israel].
    Klepfish A; Silbershatz I; Lugassy G; Shimoni A; Mittelman M
    Harefuah; 2013 Oct; 152(10):591-4, 624. PubMed ID: 24450031
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Very-Low-Dose Decitabine Is Effective in Treating Intermediate- or High-Risk Myelodysplastic Syndrome.
    Li H; Wang L; Wu Y; Su L; Zhao H; Zhang Y; Wang Z; Huang D; Huang Z; Wu X; Li X; Ye F; Yu F; Liu H; Wang JW; Cong J; Sun W; Chen HR; Wang J; Han B
    Acta Haematol; 2017; 138(3):168-174. PubMed ID: 29045939
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.
    Duchmann M; Braun T; Micol JB; Platzbecker U; Park S; Pilorge S; Beyne-Rauzy O; Vey N; Sébert M; Gruson B; Dumas PY; Guieze R; Chretien ML; Laribi K; Chait Y; Legros L; Sahnes L; Hirsch P; Salanoubat C; Solary E; Fenaux P; Itzykson R
    Blood Cancer J; 2017 May; 7(5):e562. PubMed ID: 28498370
    [No Abstract]   [Full Text] [Related]  

  • 59. A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.
    Zeidan AM; Stahl M; Sekeres MA; Steensma DP; Komrokji RS; Gore SD
    Cancer; 2017 Oct; 123(19):3662-3672. PubMed ID: 28759108
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epigenetic therapy with decitabine for myelodysplasia and leukemia.
    Wijermans P; Lübert M
    Future Oncol; 2005 Oct; 1(5):585-91. PubMed ID: 16556035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.